Accès ouvert · CC BY

Widespread pain syndrome in long COVID-19: melatonin as an adjuvant treatment

Article scientifique 2025 Sciences de la santé › Santé publique › Santé mondiale (OCDE 3.3) Anglais

Résumé

Long coronavirus disease 2019 (LC19) represents a complex global health challenge. Survivors frequently report persistent problems like widespread pain syndrome (WPS), cognitive dysfunction, cardiovascular complications, and sleep disturbances. These health problems, which are worsened by oxidative stress and inflammaging, open the prospect of treatment strategies targeting these mechanisms. Melatonin is a potential option for treating LC19 problems because of its anti-inflammatory, antioxidant, and pain-modulating properties. Melatonin targets shared pathological pathways, offering a promising approach to reducing inflammation, oxidative stress, and neuroendocrine dysfunction. The present mini-review explores the therapeutic potential of melatonin in the treatment of LC19, focusing on its effects on WPS and inflammation.

Citer ce document

Souissi, A., Prieto-González, P., & Saad, H. B. (2025). Widespread pain syndrome in long COVID-19: melatonin as an adjuvant treatment. Frontiers in Pain Research. https://doi.org/10.3389/fpain.2025.1609095

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 28/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 13

Téléchargements (hors robots) : 0

Méthode de comptage